📣 VC round data is live. Check it out!
- Public Comps
- Trinity Biotech
Trinity Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Trinity Biotech and similar public comparables like Iconovo, Spineguard, Lifecare, Renalytix and more.
Trinity Biotech Overview
About Trinity Biotech
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Founded
1992
HQ

Employees
401
Website
Sectors
Financials (FY)
EV
$144M
Valuation Multiples
Start free trialTrinity Biotech Financials
Trinity Biotech reported last fiscal year revenue of $44M and negative EBITDA of ($21M).
In the same fiscal year, Trinity Biotech generated $17M in gross profit, ($21M) in EBITDA losses, and had net loss of ($37M).
Revenue (LTM)
Trinity Biotech P&L
In the most recent fiscal year, Trinity Biotech reported revenue of $44M and EBITDA of ($21M).
Trinity Biotech is unprofitable as of last fiscal year, with gross margin of 39%, EBITDA margin of (49%), and net margin of (85%).
Financial data powered by Morningstar, Inc.
Trinity Biotech Stock Performance
Trinity Biotech has current market cap of $11M, and enterprise value of $144M.
Market Cap Evolution
Trinity Biotech's stock price is $0.57.
Trinity Biotech share price decreased by 6.3% in the last 30 days, and by 12.1% in the last year.
Trinity Biotech has an EPS (earnings per share) of $-1.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $144M | $11M | -0.9% | -6.3% | -21.5% | -12.1% | $-1.85 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTrinity Biotech Valuation Multiples
Trinity Biotech trades at 3.3x EV/Revenue multiple, and (6.7x) EV/EBITDA.
EV / Revenue (LTM)
Trinity Biotech Financial Valuation Multiples
As of May 20, 2026, Trinity Biotech has market cap of $11M and EV of $144M.
Trinity Biotech has a P/E ratio of (0.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Trinity Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Trinity Biotech Margins & Growth Rates
In the most recent fiscal year, Trinity Biotech reported gross margin of 39%, EBITDA margin of (49%), and net margin of (85%).
Trinity Biotech Margins
Trinity Biotech Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Trinity Biotech Operational KPIs
Trinity Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Trinity Biotech Competitors
Trinity Biotech competitors include Iconovo, Spineguard, Lifecare, Renalytix, Jana Medical Company, Allurion, Scandinavian Medical, Subgen AI, Scandinavian ChemoTech and Arcoma.
Most Trinity Biotech public comparables operate across Medical Devices.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 59.8x | 5.6x | (2.0x) | (2.0x) | |||
| 2.4x | 2.2x | (8.4x) | (12.5x) | |||
| 1807.3x | 106.0x | (1.8x) | (2.1x) | |||
| 3.4x | 3.4x | (0.5x) | — | |||
| 0.8x | — | (2.1x) | — | |||
| — | 2.3x | — | — | |||
| 0.6x | 0.6x | 12.9x | 17.5x | |||
| 0.4x | — | (9.9x) | — | |||
This data is available for Pro users. Sign up to see all Trinity Biotech competitors and their valuation data. Start Free Trial | ||||||
Trinity Biotech M&A Activity
Trinity Biotech has acquired 2 companies to date.
Last acquisition by Trinity Biotech was on October 25th 2024. Trinity Biotech acquired EpiCapture for $3M (EV/Revenue multiple of ).
Latest Acquisitions by Trinity Biotech
| Description | EpiCapture is a diagnostics company developing non-invasive urine-based tests for detecting aggressive prostate and bladder cancers. Based in the United Kingdom, the firm employs epigenetic biomarker technology to identify high-risk cases with greater than 90 percent specificity in early validation studies. Its assays target methylation patterns associated with tumor progression, enabling earlier intervention than traditional PSA screening. EpiCapture collaborates with NHS trusts and urology clinics for clinical deployment, focusing on improving patient outcomes through liquid biopsy methods. The platform processes samples in under two hours using standard lab equipment. | Metabolomic Diagnostics is a deep-tech company developing biomarker-based diagnostics for complex diseases like cancer and neurodegeneration. Headquartered in the United Kingdom, it pipelines panels from discovery to clinical assays using mass spectrometry. The firm validates tests for lab integration with partners in NHS and private clinics. Metabolomic Diagnostics targets multi-omics signatures for personalized medicine applications. |
| HQ Country | ||
| HQ City | Dublin | Cork |
| Deal Date | 25 Oct 2024 | 24 Sep 2024 |
| Valuation | $3M | $1M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Trinity Biotech acquisitions and their M&A valuation multiples. Start Free Trial | ||
Trinity Biotech Investment Activity
Trinity Biotech has invested in 2 companies to date.
Latest investment by Trinity Biotech was on January 15th 2025. Trinity Biotech invested in Novus Diagnostics in their $5M Seed round (EV/Revenue multiple of ).
Latest Investments by Trinity Biotech
| Description | Novus Diagnostics is a medtech company developing a sample-to-answer diagnostic platform for sepsis that processes whole blood samples. Its device rapidly detects and classifies bacterial and fungal pathogens within one hour, aiding critical care decisions in hospitals. Headquartered in Belfast, Northern Ireland, Novus focuses on point-of-care testing to reduce sepsis mortality rates through early identification. | Novus Diagnostics is a medtech company developing a sample-to-answer diagnostic platform for sepsis that processes whole blood samples. Its device rapidly detects and classifies bacterial and fungal pathogens within one hour, aiding critical care decisions in hospitals. Headquartered in Belfast, Northern Ireland, Novus focuses on point-of-care testing to reduce sepsis mortality rates through early identification. | imaware is a health technology company offering at-home diagnostic tests for conditions in men's health, women's health, allergies, autoimmune diseases, genetics, and infectious diseases like COVID-19. Its patient platform includes CLIA/CAP-certified lab analysis, telehealth consultations, and logistics for seamless care delivery. imaware partners with employers, providers, and brands to provide monitoring solutions across the United States. The digitally-native model supports screening, therapy guidance, and compliance, headquartered in New York with nationwide shipping. |
| HQ Country | |||
| HQ City | Dublin | Dublin | Austin, TX |
| Deal Date | 15 Jan 2025 | 25 Oct 2024 | 9 Jan 2023 |
| Round | Seed | Strategic investment | Series A |
| Raised | $5M | $3M | $6M |
| Investors | Business Venture Partners; Irrus Investments; Trinity Biotech | Trinity Biotech | Trinity Biotech |
| Valuation | undisclosed | $20M | undisclosed |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Trinity Biotech investments and their VC round multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Trinity Biotech
| When was Trinity Biotech founded? | Trinity Biotech was founded in 1992. |
| Where is Trinity Biotech headquartered? | Trinity Biotech is headquartered in Ireland. |
| How many employees does Trinity Biotech have? | As of today, Trinity Biotech has over 401 employees. |
| Who is the CEO of Trinity Biotech? | Trinity Biotech's CEO is John Gillard. |
| Is Trinity Biotech publicly listed? | Yes, Trinity Biotech is a public company listed on Nasdaq. |
| What is the stock symbol of Trinity Biotech? | Trinity Biotech trades under TRIB ticker. |
| When did Trinity Biotech go public? | Trinity Biotech went public in 1992. |
| Who are competitors of Trinity Biotech? | Trinity Biotech main competitors include Iconovo, Spineguard, Lifecare, Renalytix, Jana Medical Company, Allurion, Scandinavian Medical, Subgen AI, Scandinavian ChemoTech, Arcoma. |
| What is the current market cap of Trinity Biotech? | Trinity Biotech's current market cap is $11M. |
| What is the current revenue of Trinity Biotech? | Trinity Biotech's last fiscal year revenue is $44M. |
| What is the current EV/Revenue multiple of Trinity Biotech? | Current revenue multiple of Trinity Biotech is 3.3x. |
| Is Trinity Biotech profitable? | No, Trinity Biotech is not profitable. |
| How many companies Trinity Biotech has acquired to date? | As of May 2026, Trinity Biotech has acquired 2 companies. |
| What was the largest acquisition by Trinity Biotech? | $3M acquisition of EpiCapture on 25th October 2024 was the largest M&A Trinity Biotech has done to date. |
| What companies Trinity Biotech acquired? | Trinity Biotech acquired EpiCapture and Metabolomic Diagnostics. |
| In how many companies Trinity Biotech has invested to date? | As of May 2026, Trinity Biotech has invested in 2 companies. |
| What was the last Trinity Biotech investment? | On 15th January 2025 Trinity Biotech invested in Novus Diagnostics, participating in a $5M Seed round, alongside Business Venture Partners and Irrus Investments. |
| In what companies Trinity Biotech invested in? | Trinity Biotech invested in imaware and Novus Diagnostics. |
See public comps similar to Trinity Biotech
Lists including Trinity Biotech
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

